Platelet Inhibition with 60 mg Ticagrelor twice daily plus 100 mg Aspirin once daily in patients after CABG

Abstract

\n Objective: To optimize the antiplatelet therapy by observing the clinical outcomes in patients after coronary artery bypass grafting (CABG) treated with 60 mg ticagrelor twice daily plus 100 mg aspirin once daily for 1 year.Methods: The observation group was composed of patients receiving 60 mg ticagrelor twice daily plus 100 mg aspirin once daily for antiplatelet therapy after CABG, whereas the control group comprised patients taking 90 mg ticagrelor twice daily plus 100 mg aspirin once daily after CABG. Results: In the intention-to-treat (ITT) analysis of saphenous vein grafts (SVGs) patency, the difference was not statistically significant [RR=0.89, 95% confidence interval (CI): 0.29–2.71; P=0.84] between the two groups. The per-protocol (PP) analysis results of the 1-year SVGs patency rates were consistent with ITT analysis. There were no notable differences in the rates of bleeding, mild dyspnea or dyspnea leading to discontinuation of the study drug between the two groups (P=0.211).Conclusions: In patients undergoing CABG, treatment with 60 mg ticagrelor twice daily plus 100 mg aspirin once daily can achieve satisfactory clinical outcomes. Besides, the rates of dyspnea in 60 mg ticagrelor treatment are significantly lower than that in 90 mg ticagrelor treatment. As a result, the 60 mg dose leads to a markedly lower discontinuation rate of the study drug and a better safety profile, which tends to provide a more attractive benefit-risk profile.